Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD

Pediatric Transplantation
Junya FujimuraKo Okumura

Abstract

Co-stimulatory molecules expressed on T cells critically regulate donor T-cell activation and are implicated in acute GVHD after allogeneic BMT. We here investigated the role of interaction between B7-related protein-1 (B7RP-1) and ICOS in murine acute GVHD model that received T cell-depleted BM cells and splenocytes. Administration of blocking anti-B7RP-1 mAb significantly reduced the lethality and symptoms in acute GVHD. A significant hypo-responsiveness of splenocytes to host alloantigen was observed in the recipient mice treated with anti-B7RP-1 mAb. Moreover, acute GVHD was significantly reduced in the recipients of T cells composed of ICOS-deficient CD8 T cells and WT CD4 T cells compared with that in the recipients of T cells composed of WT CD8 T cells and ICOS-deficient CD4 T cells. These results suggested that B7RP-1/ICOS co-stimulatory signal plays a role in the activation of alloantigen-reactive donor T cells, particularly in CD8 T cells, in murine acute GVHD model, and that the blockade of B7RP-1/ICOS interaction may be useful for selectively manipulating allo-reactive T cells in the recipients with acute GVHD.

References

Jun 15, 1990·Science·R H Schwartz
Sep 1, 1986·Transplantation·M M Bortin, A A Rimm
Sep 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E D Thomas
Feb 1, 1993·European Journal of Immunology·R D AllenC L Sidman
Jan 1, 1996·Annual Review of Immunology·D J LenschowJ A Bluestone
Apr 15, 1997·Transplantation·D E SpeiserP S Ohashi
Jan 5, 2000·Nature·S K YoshinagaG Senaldi
Feb 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·V LingM Collins
Apr 4, 2000·Current Biology : CB·D BrodieS J Davis
Apr 13, 2000·European Journal of Immunology·H W MagesR A Kroczek
Jun 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J J WallinW C Sha
Jun 29, 2001·Nature Immunology·E OzkaynakW W Hancock
Nov 15, 2002·European Journal of Immunology·Edward M BertramTania H Watts
Jul 17, 2003·The Journal of Clinical Investigation·Hiroshi HaradaMohamed H Sayegh
Sep 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hideyuki IwaiMiyuki Azuma
Nov 18, 2003·Immunological Reviews·David M Rothstein, Mohamed H Sayegh
Jan 26, 2005·International Immunology·Masashi WatanabeRyo Abe
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masashi WatanabeRyo Abe
May 10, 2005·Transplantation·Hisanori KashizukaMohamed H Sayegh
Jun 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xue-Zhong YuChen Dong
Jun 29, 2007·Trends in Immunology·Laurent SabbaghTania H Watts
Jan 1, 1994·Mediators of Inflammation·A C KnulstH F Savelkoul
Nov 4, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A D SchenkA Valujskikh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.